Alexander J. Lenvik

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, <i>In Vivo</i> Expansion, and Enhanced Function

Daniel A. Vallera, Martin Felices, Ron McElmurry et al. · Clinical Cancer Research · 2016 · 368 citations · Full text

Life Sciences, Immunology, Oncology +17

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

Martin Felices, Alexander J. Lenvik, Ron McElmurry et al. · JCI Insight · 2018 · 261 citations · Full text

Medicine, Immunology, Oncology +17

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Michelle Gleason, Julie A. Ross, Erica D. Warlick et al. · Blood · 2014 · 258 citations · Full text

Life Sciences, Cell Biology, Immunology +13

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer

Martin Felices, Sami Chu, Behiye Kodal et al. · Gynecologic Oncology · 2017 · 141 citations

Life Sciences, Immunology, Oncology +16

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

Jörg Schmohl, Martin Felices, Felix Oh et al. · Cancer Research and Treatment · 2017 · 87 citations · Full text

Medicine, Immunology, Oncology +17